Oncotarget

Research Papers:

Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network

Yubi Lin, Siqi He, Ruiling Feng, Zhe Xu, Wanqun Chen, Zifeng Huang, Yang Liu, Qianhuan Zhang, Bin Zhang, Kejian Wang _ and Shulin Wu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:57003-57011. https://doi.org/10.18632/oncotarget.18504

Metrics: PDF 2489 views  |   HTML 3030 views  |   ?  


Abstract

Yubi Lin1,2, Siqi He1,2, Ruiling Feng1,2, Zhe Xu3, Wanqun Chen4, Zifeng Huang1,2,Yang Liu1, Qianhuan Zhang1, Bin Zhang1, Kejian Wang5 and Shulin Wu1

1Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences and Medical School of South China University of Technology, Guangzhou 510080, P.R. China

2The First Affiliated Hospital of Jinan University, Guangzhou 510630, P.R. China

3Division of Cardiac Surgery, First Affiliated Hospital of Sun-Yat-sen University, Guangzhou 510080, P.R. China

4Department of Biochemistry and Molecular Biology, Medical College, Jinan University, Guangzhou 510632, P.R. China

5Lin He’s Academician Workstation of New Medicine and Clinical Translation at The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou 510150, P.R. China

Correspondence to:

Kejian Wang, email: [email protected]

Shulin Wu, email: [email protected]

Keywords: digoxin, atrial fibrillation, heart failure, anemia, FDA adverse event reporting system

Received: March 13, 2017    Accepted: April 25, 2017    Published: June 16, 2017

ABSTRACT

Digoxin is widely used to treat various heart conditions. In order to clarify the association between digoxin and anemia adverse reaction, we inspected case reports submitted to the FDA Adverse Event Reporting System (FAERS) between January 2004 and December 2015. These reports involved 75618 atrial fibrillation patients and 15699 heart failure patients. Compared to other therapies, digoxin treatment was significantly more likely to be concurrent with anemia adverse reaction among both atrial fibrillation patients (pooled OR = 1.38, 95% CI 1.14–1.68, P-value = 0.001) and heart failure patients (pooled OR =1.50, 95% CI 1.33–1.59–, P =4.27×10-5). We further explored previously published evidences and found 821 human genes directly or indirectly interacting with digoxin. Functional analysis indicated that these genes were significantly enriched in the biological processes of iron transport, which are closely related to iron deficiency anemia. Taken together, our retrospective analysis demonstrated the significant association between digoxin treatment and anemia adverse reaction, which should be seriously considered in clinical practice. Functional enrichment analysis on digoxin-related genes warranted subsequent research on the underlying toxicological mechanisms.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18504